Posted by AGORACOM
at 4:26 PM on Tuesday, July 27th, 2021
Xali Gold ( XGC:TSXV ) has assembled a Western Mexico project portfolio of gold assets and have developed a strategy for organic growth to exploit its Flagship Gold Project El Oro, a prolific high-grade gold-silver epithermal vein system.
Xali has acquired gold and silver projects with near surface exploration potential & near-term production potential:
El Dorado Gold-Silver Project:
Rights to the El Dorado gold and silver historic mines was the initial step in this strategy, providing Xali the right to explore and produce gold, silver and other metals for life of mine.
Cocula Gold Project: profit-sharing agreement
Near term, low cost production potential by leaching and/or flotation
Retain 70% of profits
Recent drill targets Identified
Acquisition of the “SDA” Plant:
The SDA Mill is a fully operational flotation plant which also includes a precious metals leach circuit – Merrill Crowe system and associated assets, licenses and agreements, suitable for treating high grade gold and silver mineralization.
These assets are being positioned to create cash flow to develop Flagship El Oro Gold District where the primary focus is the past producing San Rafael Vein; 2.4km strike of high-grade Epithermal veins.
The project covers 20 veins with past production and more than 57 veins in total and approximately 6.4 million ounces of gold and 74 million ounces of silver were reported to have been produced from just two of these veins. Historical Average grades: 10-12 g/t gold & 120-160 g/t silver
Xali has identified 31 exploration targets
Flooding in one section of the San Rafael vein in 1929 resulted in the other two sections flooding and work ceasing abruptly and unexpectedly. El Oro was not mined out. The financial benefits from Western Mexico operations will translate across platforms to strengthen the Company’s efforts to explore and potentially mine areas demonstrated to contain mineralization of value
Chief Medical Officer Dr. Reid Robison explains the three pillars of Ketamine therapy and the steps we take to prevent misuse.
“I’ve never had a client who we’ve done the appropriate process with who has entered into a troubled relationship with ketamine through the course of their treatment.”
Our Chief Medical Officer joins Health Professional Radio to discuss psychedelic medicine and our rapid expansion phase as we grow our network of clinics, research sites and therapeutic retreats specialized in psychedelic medicine.
“We’re expanding even more with the need that has come up through the pandemic and the willingness to look towards new and improved ways of approaching our mental health”
We are pleased to announce that we have submitted our application to have our common shares posted for trading on the OTCQB® Venture Market, a U.S. trading platform operated by the OTC Markets Group, Inc.
“Having the Company’s common shares posted for trading on the OTCQB and providing a more efficient way of trading our shares will be an important milestone in our strategy of building awareness and enhancing accessibility amongst United States investors looking for exposure to the growth potential of Novamind’s mental health and psychedelic medicine business,” said Yaron Conforti, CEO and Director of Novamind.
A groundbreaking Yale study has uncovered a new dimension in understanding how psychedelics affect us: with small, physical changes to the brain. The study tracked how psilocybin, the active molecule in psychedelic mushrooms, not only has significant and long-lasting effects on mood but actually stimulates growth of new neuronal connections within the brain.
Governments around the world accelerated the clinical research process to develop vaccines for the Covid-19 health crisis. So why can’t we do the same for drugs to treat the mental health crisis? Monnica Williams and Morgan Campbell argue the point in the Baltimore Sun, comparing the investment in mental health treatment with physical health treatment: Investment in psychiatric therapies has remained very low compared to the burden of diseases, with $1.80 per $1,000 in disease burden for major depression and $0.40 for bipolar disorder compared to $9.40 for COPD, $7.60 for diabetes and $75.50 for cancer.
The popularity of using ketamine as a psychedelic treatment is only growing, according to ABC News. Less than 60 ketamine clinics existed in the United States in 2015. In 2018, that number climbed to over 300. With over 7,000 ketamine treatments to date, Novamind remains one of the busiest and most experienced ketamine practices in America.
Michael Pollan, the award-winning journalist who wrote “How to Change Your Mind,” a comprehensive examination of psychedelics history and his personal experience, is back. His new book contrasts the effects of three plant-based substances: caffeine, opium and mescaline. His section on mescaline further destigmatizes psychedelics through a critical and journalistic lens.
Posted by AGORACOM-JC
at 4:10 PM on Friday, July 16th, 2021
FOBI AI is a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement for enterprise level retailers.
More than just lip service, these are just a sample of the major milestones reached by $FOBI over the past 9 months:
Strategic Alliance with global data leader – NeilsonIQ – to “Transform Retail Sector”
A partnership with NTT DATA, a top-ranked global IoT services company, and subsidiary of Nippon Telegraph and Telephone, the world’s 4th largest telecom company, ranked 55th In Fortune Global 500.
Approved for Oracle Partner Network
Pilot Projects with Sobeys, TELUS, Certas and other national level retailers
Multi-Year Direct Seller Agreement With TELUS, in which TELUS resells FOBI solutions to national business customers
Posted by AGORACOM
at 4:35 PM on Thursday, July 15th, 2021
Fabled Silver Gold (FCO TSXV) ( FBSGF: OTC ) controls 100% of the Santa Maria mine gold and silver property in Mexico. It is a high grade silver gold property that is situated right in the middle of the Mexican Epithermal silver gold belt that has reportedly produced more silver than any other equivalent area in the entire planet.
To say it’s a mining friendly jurisdiction is an understatement.
Multiple major operators are in the vicinity and it’s already got a silver equivalent 43-101 of 3.2m ounces, but is looking to add to that significantly with recent intercepts of 2269 g/t silver.
That is not a typo, in other words it is also 2.269 kilos AgEq or 72 troy ounce.
Just recently, Fabled encountered a new, previously unknown gold zone with the discovery of a new high grade gold system with values up 10.85 g/t Au within 30.7m grading 161.09 Ag Eq
This quote from Peter J. Hawley, CEO and President sums up the future potential aptly:
……“ we have found a new, never discovered high grade gold mineral domain system, with silver credits, over consistent widths in an area never explored, and which remains open to the west and at depth, plunging 45 degrees to the west and open in all directions for expansion.
Recent underground diamond drilling also intercepted 4 Zones of Silver Mineralization including 314.35 g/t Ag Eq over 0.80m.
Fabled is intent on proving Santa Maria is bigger and of potentially higher grade than the market understands and is well on its way with intercepts such as these.
Sit back with your favorite beverage as Peter Hawley explains the importance of the latest discovery within the context of the Fabled corporate presentation
The Santa Maria Project is poised to deliver as exploration continues to deliver discoveries through both above and underground drill programs.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison, Dr. Steve Thayer, and Derick Moody, PA-C discuss whether or not the mystical experience caused by many psychedelic medicines is a necessary factor for the healing they promote.
Microdose covers ketamine’s history as an off-label treatment for depression, the FDA approval of Spravatoᵀᴹ (esketamine) and what the future looks like for these drugs. CEO Yaron Conforti and CMO Dr. Reid Robison were both interviewed for the article.
“Cost and accessibility are universal challenges we face in our healthcare system, and these will also apply to psilocybin, MDMA, and nearly every drug that comes to market, at least during the initial years of patent exclusivity,” said Robison.
We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a study titled “A phase IIb, randomized, double blind, two arm study to investigate the effects of BNC210 tablet formulation compared to placebo in adults with post-traumatic stress disorder”.
“This clinical trial leverages CCR’s established track record studying novel treatments for PTSD and other difficult to treat mental health conditions.” said Dr. Reid Robison, Chief Medical Officer of Novamind.
Larger and stronger neural connections. According to new research out of Yale, it’s all about the increased density of dendritic spines. “Small protrusions found on nerve cells which aid in the transmission of information between neurons. Chronic stress and depression are known to reduce the number of these neuronal connections.” If psilocybin can create larger and stronger neural connections, the potential for treating depression and creating lasting change improves significantly.
While “there have been no research studies in humans showing that LSD can treat allergies of any kind” one patent application hopes that one day LSD will be able to treat food allergies. The article references a story about a claim (not research- or evidence-based) that LSD cured a lifelong cat allergy and goes into more detail about the patent process and what might stand in the way of this one getting approved. “It’s based on luck.” And it’s another entrant to the race to patent psychedelics.
Posted by AGORACOM-JC
at 4:53 PM on Tuesday, July 6th, 2021
HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing a portfolio of high value-added silicon products sought after by battery and electric vehicle manufacturers.
If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following:
To understand the importance and the implications of this milestone, this excerpt from the press release says it all:
” Demand for higher purity Silicon, materials that the PUREVAP QRR was designed to produce – but one that traditional silicon producers have a difficult time making, is about to enter a massive growth phase, driven by worldwide demand from the silicones, solar, and batteries industries. The Covid-19 pandemic accelerated the closing of old inefficient traditional Silicon plants and combining this with the chronic under investment in new conventional Silicon plants that occurred in the past decade, and the need for more efficient and environmentally friendly processes has created a perfect storm for the industry. HPQ should be a key beneficiary of this new reality.”
Today, thanks to HPQ’s great progress on its silicon mission, the Company announced “An Agreement to Develop a New Environmentally Friendly Process to Manufacture Fumed Silica” What is Fumed Silica? Suffice it to say, it is in heavy demand right now but current producers are going to run into strong environmental “ESG” headwinds as the industry is now moving towards clean and verified Fumed Silica that HPQ Silicon believes it will be able to deliver thanks to its powerful relationship with ESG driven PyroGenesis Canada. The market for Fumed Silica is set to hit $USD 2.2 Billion in 2022 and CEO Tourillon wasn’t shy about his confidence in the Company’s potential to win market share with this quote:
““The business opportunity that this represent should not be underestimated and could be as significant as the ones represented by the PUREVAP™ family of processes we are developing with PyroGenesis”
Watch this great interview with $HPQ CEO Bernard Tourillon – especially the last 13 minutes – to get the full picture!
Posted by Nicole Rojas
at 4:50 PM on Thursday, June 24th, 2021
If you’ve ever thought to yourself “how great would it be if my favourite comfort foods could only be healthier” than meet Boosh … an Award Winning Plant-Based Comfort Food Company whose products include:
Mac N Cheese and Peas
Veggie Bolognese
and other “Heat and Eat” delicious comfort foods that are
Multiple Award winning
100% Plant-based, GMO and Gluten Free
The company has only been a public entity for one month and it’s already making waves.
Expanded to 300+ stores in less than 18 months Including
Whole Foods, Safeway, Metro, IGA, Choices + many other retailers
An alliance with Beyond Meat
Distributed by UNFI – one of the largest distributors in North America
Expanding into refrigerated section with new SKUs
Strong insider ownership at 29%
Growth of The Plant-Based food Market is Undeniable…
The plant-based food market is expected to grow at a CAGR of 11.9% from 2020 to 2027 to reach $74.2 billion by 2027 according to ResearchAndMarkets.com.
Watch this powerful interview with Boosh CEO Jim Pakulis.
Posted by AGORACOM
at 9:09 AM on Thursday, June 24th, 2021
Harborside Inc. is one of the oldest and most respected cannabis retailers in California, operating three of the major dispensaries in the San Francisco Bay Area and a cultivation/production facility in Salinas, California and awarded one of the first six medical cannabis licenses granted in the United States.
Harborside hold cannabis licenses for retail, distribution, cultivation, nursery, and manufacturing.
With California being one of the largest cannabis markets in the world, Harborside Retail operations command 3% of California’s entire retail market and operations have generated over $400M in cumulative sales since inception
Fourth Quarter and Full Year 2020 Financial Results
Full Year 2020 Gross Revenues Expand 29% Year-Over-Year to $63.4 Million Full Year
2020 Adjusted EBITDA grows to $7.4 Million From an Adjusted EBITDA Loss of $8.9 Million in 2019(1)
Reports Fourth Quarter Gross Revenues of $13.1 Million and Positive Adjusted EBITDA of $0.7 Million(1)
Fourth Quarter Total Gross Margins improved from 22.1% to 49.9%(1), Driven by Improved Harvest Yields, Higher Wholesale Volumes, and Improved Operating Leverage Supported by Tight Expense Management
2020 Operational Highlights
Closed upsized private placement for gross proceeds of approximately C$35.1 million
Secured a $12 million revolving credit facility
Completed a $5 million strategic investment in Loudpack, a premier California cannabis company
Completed the acquisition of a 21% interest in a San Francisco Dispensary in the historic Haight-Ashbury District
Sit back, relax and watch this powerful interview with Matt hawkins as he demonstrates the powerful growth potential legislation is anticipated to have on operations.
Posted by AGORACOM-JC
at 2:23 PM on Wednesday, June 23rd, 2021
HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing a portfolio of high value-added silicon products sought after by battery and electric vehicle manufacturers.
If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following
To understand the importance and the implications of this milestone, this excerpt from the press release says it all:
” Demand for higher purity Silicon, materials that the PUREVAP QRR was designed to produce – but one that traditional silicon producers have a difficult time making, is about to enter a massive growth phase, driven by worldwide demand from the silicones, solar, and batteries industries. The Covid-19 pandemic accelerated the closing of old inefficient traditional Silicon plants and combining this with the chronic under investment in new conventional Silicon plants that occurred in the past decade, and the need for more efficient and environmentally friendly processes has created a perfect storm for the industry. HPQ should be a key beneficiary of this new reality.”
Posted by AGORACOM-JC
at 9:06 AM on Saturday, June 19th, 2021
A weekly summary of Novamind news and media, including the announcement of a US$1,000,000 strategic investment in a Stealth Mode Drug Development Company.
“Novamind has over five years of operational expertise with psychedelic medicine, a track record of innovative treatment protocol development, and strong clinical research partnerships with blue-chip pharmaceutical companies,” said CEO Yaron Conforti. “I’m excited to share our vision for the next chapter of mental health treatment at the Conference.”
The Strategic Investment leverages Novamind’s expertise in patient recruitment and patient management for the Investee’s development of novel treatments for neuropsychiatric disorders.
Global News paints a compelling picture about the need for psychedelic-assisted therapy in Canada. “I just had so many different experiences, where all my questions that I had written out, everything was answered for me.” says Laurie Brooks, who was diagnosed with colon cancer at age 54. “I’m able now to deal with the emotions as they come, and to sit with them and hold them.”
It’s been a year of progress as many health breakthroughs happened while the public’s attention was rightfully focused on a Covid vaccine. Time covers some significant steps forward, including a malaria vaccine that could help save some 400,000 lives a year and the promising results of MDMA and psilocybin studies. It’s important to note the therapy aspect of the psychedelic studies. Both MDMA and psilocybin were given to participants in conjunction with therapy. Yes, these drugs are powerful and help provide the right mindset for improving mental health, but it’s the therapy that really creates lasting change. And it’s why that’s such a big part of what we do at Novamind.
Congratulations to Atai Life on listing to the Nasdaq. As an early strategic investor, we look forward to seeing Atai continue to deliver on its mission of “pioneering the development of highly effective mental health treatments.” Christian Angermayer
